FOXM1 and glioblastoma: Consistent with this, in a recent study, FoxM1 was shown to enhance the nuclear localization of β-catenin, regulate the expression of target genes of Wnt and gliomagenesis; similarly, close correlation was demonstrated between Wnt/β-catenin signaling, GBM progression, and patient prognosis [7], as well as cancer stemness, self-renewal, and resistance to therapy [8,9], thus, reinforcing the notion that the targeting of Wnt/β-catenin-mediated oncogenicity, self-renewal, and therapy-resistance may represent a critically efficacious anti-GBM treatment strategy.